{"pmid":32298218,"title":"Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.","text":["Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.","A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel(R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses.","Hum Vaccin Immunother","Chen, Wen-Hsiang","Hotez, Peter J","Bottazzi, Maria Elena","32298218"],"abstract":["A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel(R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses."],"journal":"Hum Vaccin Immunother","authors":["Chen, Wen-Hsiang","Hotez, Peter J","Bottazzi, Maria Elena"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298218","week":"202016|Apr 13 - Apr 19","doi":"10.1080/21645515.2020.1740560","keywords":["COVID-19","Heterologous vaccine","SARS","SARS-CoV-2","coronavirus","receptor-binding domain","subunit vaccine"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664266651210612737,"score":8.233237,"similar":[{"pmid":32203189,"title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.","text":["Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.","The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.","Cell Mol Immunol","Tai, Wanbo","He, Lei","Zhang, Xiujuan","Pu, Jing","Voronin, Denis","Jiang, Shibo","Zhou, Yusen","Du, Lanying","32203189"],"abstract":["The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection."],"journal":"Cell Mol Immunol","authors":["Tai, Wanbo","He, Lei","Zhang, Xiujuan","Pu, Jing","Voronin, Denis","Jiang, Shibo","Zhou, Yusen","Du, Lanying"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203189","week":"202013|Mar 23 - Mar 29","doi":"10.1038/s41423-020-0400-4","keywords":["2019 novel coronavirus","SARS-CoV-2","cross-neutralization","receptor-binding domain","spike protein","viral inhibitor"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352133627412480,"score":890.0791},{"pmid":32065055,"pmcid":"PMC7048180","title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","text":["Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.","Emerg Microbes Infect","Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei","32065055"],"abstract":["The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."],"journal":"Emerg Microbes Infect","authors":["Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei"],"date":"2020-02-18T11:00:00Z","year":2020,"_id":"32065055","week":"20208|Feb 17 - Feb 23","doi":"10.1080/22221751.2020.1729069","keywords":["*2019-nCoV","*ACE2","*RBD","*SARS-CoV","*monoclonal antibody"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352134621462528,"score":753.5142},{"pmid":32245784,"title":"A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.","text":["A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.","The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 A. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the \"up\" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2.","Science","Yuan, Meng","Wu, Nicholas C","Zhu, Xueyong","Lee, Chang-Chun D","So, Ray T Y","Lv, Huibin","Mok, Chris K P","Wilson, Ian A","32245784"],"abstract":["The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 A. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the \"up\" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2."],"journal":"Science","authors":["Yuan, Meng","Wu, Nicholas C","Zhu, Xueyong","Lee, Chang-Chun D","So, Ray T Y","Lv, Huibin","Mok, Chris K P","Wilson, Ian A"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245784","week":"202014|Mar 30 - Apr 05","doi":"10.1126/science.abb7269","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135872413696,"score":728.5066},{"pmid":32275855,"title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","text":["Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.","Cell","Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun","32275855"],"abstract":["The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus."],"journal":"Cell","authors":["Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275855","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cell.2020.03.045","keywords":["ACE2","CTD","SARS-CoV-2","crystal structure","immunogenicity","receptor","receptor binding domain"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663712077925056512,"score":691.1041},{"pmid":32225176,"title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.","text":["Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.","A novel and highly pathogenic coronavirus (SARS-CoV-2) has caused an outbreak in Wuhan city, Hubei province of China since December 2019, and soon spread nationwide and spilled over to other countries around the world(1-3). To better understand the initial step of infection at an atomic level, we determined the crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) bound to the cell receptor ACE2 at 2.45 A resolution. The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also utilizes ACE2 as the cell receptor(4). Structural analysis identified residues in the SARS-CoV-2 RBD that are critical for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly argue for convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses(1-3,5). The epitopes of two SARS-CoV antibodies targeting the RBD are also analysed with the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.","Nature","Lan, Jun","Ge, Jiwan","Yu, Jinfang","Shan, Sisi","Zhou, Huan","Fan, Shilong","Zhang, Qi","Shi, Xuanling","Wang, Qisheng","Zhang, Linqi","Wang, Xinquan","32225176"],"abstract":["A novel and highly pathogenic coronavirus (SARS-CoV-2) has caused an outbreak in Wuhan city, Hubei province of China since December 2019, and soon spread nationwide and spilled over to other countries around the world(1-3). To better understand the initial step of infection at an atomic level, we determined the crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) bound to the cell receptor ACE2 at 2.45 A resolution. The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also utilizes ACE2 as the cell receptor(4). Structural analysis identified residues in the SARS-CoV-2 RBD that are critical for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly argue for convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses(1-3,5). The epitopes of two SARS-CoV antibodies targeting the RBD are also analysed with the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies."],"journal":"Nature","authors":["Lan, Jun","Ge, Jiwan","Yu, Jinfang","Shan, Sisi","Zhou, Huan","Fan, Shilong","Zhang, Qi","Shi, Xuanling","Wang, Qisheng","Zhang, Linqi","Wang, Xinquan"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32225176","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41586-020-2180-5","source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135273676800,"score":618.44824}]}